HSBC Bank Plc : Form 8.5 (EPT/RI) - Millennium & Copthorne

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
93
HSBC Bank Plc : Form 8.5 (EPT/RI) - Millennium & Copthorne Hotels PLC

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: HSBC BANK PLC
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree   Millennium & Copthorne Hotels PLC
(c) Name of the party to the offer with which exempt principal trader is connected:   City Development Limited
(d) Date dealing undertaken:   14 th Dec 2017
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A"   No

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received (GBP) Lowest price per unit paid/received (GBP)
Ordinary Shares     Purchase     66,523   590.000 p   566.000 p
Ordinary Shares     Sale     66,523   590.000 p   566.000 p

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP)
         

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
    None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None
Date of disclosure: 15 th Dec 2017
Contact name: Satabdi Dasgupta
Telephone number: 0207 088 2000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 6

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 5

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 1

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched: Are SecureWorks Shareholders Treated Fairly?

Updated Category News Views 58

Investigation Into SecureWorks Corp. Shareholder Fairness In recent developments, Ademi LLP has initiated an investigation into SecureWorks Corp. (NASDAQ: SCWX) concerning possible breaches of fiduciary duty related to its upcoming transaction with Sophos. This investigation raises important questions about whether SecureWorks is providing fair value to its public...

Continue Reading
VIAVI Partners with Telefónica HISPAM for Network Solutions

Updated Category News Views 94

VIAVI Partners with Telefónica HISPAM for Enhanced Network Management Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) recently secured a strategic agreement to provide advanced automated network inventory management for Telefónica Hispanoamérica (HISPAM). This collaboration aims to leverage Viavi's innovative NITRO AIOps solution to improve network operations throughout...

Continue Reading
Crédit Agricole Assurances Reports Remarkable Growth in 2024

Updated Category News Views 68

Crédit Agricole Assurances Reports Remarkable Growth in 2024 Crédit Agricole Assurances recently revealed their impressive performance for the first nine months of 2024, showcasing an 18.2% increase in total revenue, amounting to €32.8 billion. This significant growth reflects the company's dedication to its clients and the effectiveness of its diverse insurance...

Continue Reading
Teads Holding Co. Announces Participation in Key Conferences

Updated Category News Views 135

Teads Holding Co. Engages Investors in Upcoming Conferences Teads Holding Co. (NASDAQ: TEAD), recognized as a leader in the advertising technology space, is gearing up for significant investor conferences this September. As the company continues to expand its influence and reach, it will showcase its innovative approach to marketing solutions at these events, emphasizing...

Continue Reading
Intelligent Vending Machines Market Growth Predictions

Updated Category News Views 68

Overview of the Intelligent Vending Machines Market The Intelligent Vending Machines market is undergoing rapid transformation, capturing the interest of both investors and consumers alike. As technology progresses at an astonishing pace, these machines are evolving from simple snack dispensers into advanced retail solutions. Currently valued at USD 22.15 billion, the...

Continue Reading